Essential Fatty Acids as Transdermal Penetration Enhancers
| Autor: | Jan L. du Preez, Joe M. Viljoen, Minja Gerber, Jeanetta du Plessis, Lindi van Zyl |
|---|---|
| Přispěvatelé: | 20855125 - Van Zyl, Lindi, 10060510 - Du Preez, Jan Lourens, 11329025 - Gerber, Minja, 10065318 - Du Plessis, Jeanetta, 11320036 - Viljoen, Johanna Magdalena |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Vitamin Administration Topical Chemistry Pharmaceutical Skin Absorption Flurbiprofen Pharmaceutical Science 02 engineering and technology Pharmacology Administration Cutaneous Pheroid™ 030226 pharmacology & pharmacy Excipients 03 medical and health sciences chemistry.chemical_compound Drug Delivery Systems 0302 clinical medicine medicine Humans Plant Oils Vitamin F Evening Primrose Oil Enhancer Transdermal chemistry.chemical_classification Arachidonic Acid Fatty Acids Essential business.industry Fatty acid Penetration (firestop) 021001 nanoscience & nanotechnology Primula Solubility Formulation chemistry Diffusion Chambers Culture Female Evening primrose oil Arachidonic acid 0210 nano-technology business medicine.drug |
| Zdroj: | Journal of Pharmaceutical Sciences. 105:188-193 |
| ISSN: | 0022-3549 1520-6017 |
| Popis: | The aim of this study was to investigate the effect of different penetration enhancers, containing essential fatty acids (EFAs), on the transdermal delivery of flurbiprofen. Evening primrose oil (EPO), vitamin F and Pheroid™ technology all contain fatty acids and were compared using a cream-based formulation. This selection was to ascertain whether EFAs solely, or EFAs in a Pheroid™ delivery system, would have a significant increase in the transdermal delivery of a compound. Membrane release studies were performed and the results indicated the following rank order for flurbiprofen release from the different formulations: vitamin F >> control > EPO >> Pheroid™. Topical skin delivery results indicated that flurbiprofen was present in the stratum corneum-epidermis and the epidermis-dermis. The average percentage flurbiprofen diffused to the receptor phase (representing human blood) indicated that the EPO formulation showed the highest average percentage diffused. The Pheroid™ formulation delivered the lowest concentration with a statistical significant difference (p < 0.05) compared to the control formulation (containing 1% flurbiprofen and no penetration enhancers). The control formulation presented the highest average flux, with the EPO formulation following the closest. It could thus be concluded that EPO is the most favourable chemical penetration enhancer when used in this formulation http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%291520-6017 National Research Foundation (NRF) of South Africa (Grants no. IFRR81178 and CPRR13091742482) and The Centre of Excellence for Pharmaceutical Sciences (Pharmacen) of the North-West University, Potchefstroom Campus, South Africa |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|